[A19-20] Ocriplasmin (vitreomacular traction) - Addendum to Commission A18-68
Last updated 04.05.2019
Project no.:
A19-20
Commission:
Commission awarded on 25.03.2019 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Head and nerves
Indication:
Vitreomacular traction, including when associated with macular hole of diameter ≤ 400 microns
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A18-68 | Ocriplasmin (vitreomacular traction, including when associated with macular hole) - Benefit assessment according to §35a Social Code Book V (reassessment after expiry of the decision) | Commission completed |
Federal Joint Committee (G-BA)
2019-04-04 A G-BA decision was published.